ES2523968T3 - Terapia de combinación antibacteriana para el tratamiento de infecciones por bacterias Gram-positivas - Google Patents

Terapia de combinación antibacteriana para el tratamiento de infecciones por bacterias Gram-positivas Download PDF

Info

Publication number
ES2523968T3
ES2523968T3 ES09784726.3T ES09784726T ES2523968T3 ES 2523968 T3 ES2523968 T3 ES 2523968T3 ES 09784726 T ES09784726 T ES 09784726T ES 2523968 T3 ES2523968 T3 ES 2523968T3
Authority
ES
Spain
Prior art keywords
gram
treatment
positive bacteria
infections
combination therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09784726.3T
Other languages
English (en)
Inventor
Malcolm Philip Young
Catherine Mary Thomas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
E Therapeutics PLC
Original Assignee
E Therapeutics PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by E Therapeutics PLC filed Critical E Therapeutics PLC
Application granted granted Critical
Publication of ES2523968T3 publication Critical patent/ES2523968T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

Una composición que comprende miconazol, y sales farmacéuticamente aceptables del mismo, y nisina, y sales farmacéuticamente aceptables de la misma, para su uso en el tratamiento de una infección a la que contribuyen o producida por bacterias Gram-positivas.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16

Claims (1)

  1. imagen1
ES09784726.3T 2008-07-18 2009-07-17 Terapia de combinación antibacteriana para el tratamiento de infecciones por bacterias Gram-positivas Active ES2523968T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0813211 2008-07-18
GBGB0813211.0A GB0813211D0 (en) 2008-07-18 2008-07-18 Antibacterial combination therapy for the treatment of gram positive bacterial infections
PCT/GB2009/001772 WO2010007381A1 (en) 2008-07-18 2009-07-17 Antibacterial combination therapy for the treatment of gram positive bacterial infections

Publications (1)

Publication Number Publication Date
ES2523968T3 true ES2523968T3 (es) 2014-12-03

Family

ID=39737300

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09784726.3T Active ES2523968T3 (es) 2008-07-18 2009-07-17 Terapia de combinación antibacteriana para el tratamiento de infecciones por bacterias Gram-positivas

Country Status (15)

Country Link
US (1) US8614179B2 (es)
EP (1) EP2328573B1 (es)
JP (1) JP6023425B2 (es)
CN (1) CN102112125B (es)
AU (1) AU2009272485B2 (es)
CA (1) CA2730826A1 (es)
CY (1) CY1116056T1 (es)
DK (1) DK2328573T3 (es)
ES (1) ES2523968T3 (es)
GB (1) GB0813211D0 (es)
HR (1) HRP20141147T1 (es)
PL (1) PL2328573T3 (es)
PT (1) PT2328573E (es)
WO (1) WO2010007381A1 (es)
ZA (1) ZA201100705B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008059258A2 (en) * 2006-11-16 2008-05-22 E-Therapeutics Limited Imidazoles for treating multi-drug resistant bacterial infections
GB0714226D0 (en) * 2007-07-20 2007-08-29 Therapeutics Ltd E anti-bacterial combination therapy
GB0813211D0 (en) 2008-07-18 2008-08-27 E Therapeutics Plc Antibacterial combination therapy for the treatment of gram positive bacterial infections
BRPI0904249B1 (pt) 2009-08-28 2018-03-06 Biolab Sanus Farmacêutica Ltda. Compostos éteres aralquil benzílicos, processo de preparação dos mesmos, uso dos referidos compostos, composição farmacêutica
CA2841272C (en) 2011-07-12 2019-01-15 Alan Bruce Montgomery Formulations of amikacin and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (vap) and ventilator associated tracheal (vat) bronchitis
US8826904B2 (en) 2011-07-12 2014-09-09 Cardeas Pharma Corporation Formulations of aminoglycoside and fosfomycin combinations and methods and systems for treatment of ventilator associated pneumonia (VAP) and ventilator associated tracheal (VAT) bronchitis
US20150238473A1 (en) 2012-09-27 2015-08-27 University Of Rochester Methods and compositions for treating infection
WO2014130655A2 (en) 2013-02-20 2014-08-28 Biolog, Inc. Compositions and methods to inactivate and/or reduce production of microbial toxins
GB201305277D0 (en) * 2013-03-22 2013-05-01 Helperby Therapeutics Ltd Novel combination and use
RU2549447C1 (ru) * 2014-03-14 2015-04-27 Алексей Игоревич Панюков Противовоспалительное антибактериальное ранозаживляющее средство
DE102014218913A1 (de) * 2014-09-19 2016-03-24 Heraeus Medical Gmbh Verfahren zur Herstellung eines antibiotischen Polymehtylmethacrylat-Knochenzementpulvers und ein antibiotisches Polymethtylmethacrylat-Knochenzementpulver
CN109512999B (zh) * 2016-03-04 2022-05-10 广州英赛特生物技术有限公司 含氧碳氢衍生物的脂肪醇作为多粘菌素的协同增效剂的应用
US10526343B2 (en) 2018-03-26 2020-01-07 University Of Sharjah Heterocyclic systems and pharmaceutical applications thereof
US10485790B1 (en) * 2018-09-13 2019-11-26 Syneurx International (Taiwan) Corp. Salts of cycloserine compounds and applications thereof
US20220125763A1 (en) * 2019-02-22 2022-04-28 Anifera Limited Compositions providing enhanced antibacterial activity against gram-positive bacteria and use thereof
WO2022257105A1 (en) * 2021-06-11 2022-12-15 The Hong Kong Polytechnic University Methods for treating bacterial cell populations
US12178790B2 (en) * 2021-08-05 2024-12-31 Jonathan SORRES Antibacterial compound isolated from Psiloxylon mauritianum and its derivatives

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3249109A (en) 1963-11-01 1966-05-03 Maeth Harry Topical dressing
US3598122A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US4144317A (en) 1975-05-30 1979-03-13 Alza Corporation Device consisting of copolymer having acetoxy groups for delivering drugs
US4262003A (en) 1975-12-08 1981-04-14 Alza Corporation Method and therapeutic system for administering scopolamine transdermally
US4307717A (en) 1977-11-07 1981-12-29 Lectec Corporation Sterile improved bandage containing a medicament
NZ210840A (en) 1984-01-18 1987-05-29 Johnson & Johnson Baby Prod Composition comprising synergistic combination of miconazole nitrate and zinc oxide
US4725439A (en) 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
HU199682B (en) * 1988-04-01 1990-03-28 Egyt Gyogyszervegyeszeti Gyar Process for producin synergetic veterinary composition
GB9224598D0 (en) * 1992-11-24 1993-01-13 Smithkline Beecham Plc Novel compositions
JP2875140B2 (ja) 1993-08-16 1999-03-24 明治製菓株式会社 抗ｍｒｓａ組成物
US6461607B1 (en) 1998-08-24 2002-10-08 Ganeden Biotech, Inc. Probiotic, lactic acid-producing bacteria and uses thereof
FR2843302B1 (fr) 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
WO2005096990A2 (en) 2004-04-02 2005-10-20 Baylor College Of Medicine Novel modification of medical prostheses
WO2008059258A2 (en) 2006-11-16 2008-05-22 E-Therapeutics Limited Imidazoles for treating multi-drug resistant bacterial infections
GB0714226D0 (en) 2007-07-20 2007-08-29 Therapeutics Ltd E anti-bacterial combination therapy
WO2009037264A2 (en) 2007-09-17 2009-03-26 Da Volterra Colonic delivery of antimicrobial agents
GB0724996D0 (en) * 2007-12-21 2008-01-30 Therapeutics Ltd E Antibacterial combination therapy for the treatment of gram positive bacterial infections
GB0813211D0 (en) 2008-07-18 2008-08-27 E Therapeutics Plc Antibacterial combination therapy for the treatment of gram positive bacterial infections

Also Published As

Publication number Publication date
US20110257078A1 (en) 2011-10-20
WO2010007381A1 (en) 2010-01-21
ZA201100705B (en) 2012-04-25
HRP20141147T1 (hr) 2015-01-30
CY1116056T1 (el) 2017-02-08
CN102112125B (zh) 2016-06-22
PL2328573T3 (pl) 2015-02-27
AU2009272485A1 (en) 2010-01-21
AU2009272485B2 (en) 2015-02-12
US8614179B2 (en) 2013-12-24
JP6023425B2 (ja) 2016-11-09
GB0813211D0 (en) 2008-08-27
CN102112125A (zh) 2011-06-29
EP2328573B1 (en) 2014-08-27
CA2730826A1 (en) 2010-01-21
PT2328573E (pt) 2014-12-03
DK2328573T3 (en) 2014-12-08
JP2012503594A (ja) 2012-02-09
EP2328573A1 (en) 2011-06-08

Similar Documents

Publication Publication Date Title
ES2613674T3 (es) Uso del organismo fúngico Pythium oligandrum
CL2008001855A1 (es) Compuestos ciclicos condensados derivados del boro; composicion farmaceutica; y uso en el tratamiento y/o prevencion de una enfermedad infecciosa.
CL2017000156A1 (es) Procedimientos para el tratamiento de paramixovirus.
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
ES2571998T3 (es) Composiciones y usos médicos de derivados del ajoeno
CL2008002228A1 (es) Compuestos derivados de imidazopiridinonas, agonista de tlr7; procedimiento de preparacion; compuestos intermediarios; composiicon farmaceutica que los comprende; y uso en infecciones virales, bacterianas y fungicas.
SV2016005274A (es) Compuestos orgánicos de monobactam para el tratamiento de infecciones bacterianas
EA033311B1 (ru) Производные бензоксаборола в качестве антибактериальных средств
MX2009009918A (es) Medicamentos combinados para el tratamiento de infecciones bacterianas.
CL2012001950A1 (es) Uso de una cepa bacteriana probiotico en la fabricacion de un medicamento o composicion nutricional en humanos o animales para alterar los patrones del sueño
AR077125A1 (es) Combinaciones farmaceuticas utiles para tratar el vhc
BR112015029367A2 (pt) terapia combinada compreendendo oxazolidinona-quinolonas para uso no tratamento de infecções bacterianas
CL2012003266A1 (es) Polisacarido de semillas de tamarindo para usarse en el tratamiento de infecciones microbianas; composicion farmacéutica y/o dermocosmética antimicrobiana que contiene dicho polisacárido; uso de un polisacárido de semilla de tamarindo ; metodo para tratar y/o prevenir a un paciente que tiene una infeccion microbiana.
CL2016001524A1 (es) Derivados antibacterianos de 1h-indazol y 1h-indol.
CL2015002755A1 (es) Composiciones antibióticas de ceftolozano.
CL2008001533A1 (es) Formulacion que comprende triazinonas y compuestos o complejos ferricos, utiles para preparar medicamentos para uso veterinario contra la coccidiosis y deficiencias de hierro.
CO6321285A2 (es) Uso de 3,11b-cis- dihidrotetrabenazina en el tratamiento de la esclerosis multiple y la mielitis autoinmunitaria
AR090569A1 (es) Agregados de nanoparticulas que contienen osteopontina y particulas que contienen calcio y/o estroncio
DOP2006000268A (es) Agentes antibacterianos
MX376475B (es) Derivado de polimixina y usos del mismo.
CO2019010001A2 (es) Antibióticos macrociclicos de amplio espectro
BR112013033759A8 (pt) Forma de dosagem unitária de um gel de base aquosa de metronidazol mucoadesivo e uso relacionado ao gel de base aquosa de metronidazol
CL2015002759A1 (es) Métodos de tratamiento de infecciones en pacientes con sobrepeso y obesos usando antibióticos
CO6382113A2 (es) Compuestos quimicos
CL2009000257A1 (es) Uso de imidazolinas 1,3 sustituidas y de sus sales fisiologicamente compatibles para el tratamiento del sindrome metabolico.